Metanoia Press · In preparation
A very short journey
N,N-Dimethyltryptamine is a classic psychedelic with a very short action. In early injection studies, effects peaked within two minutes and were negligible by thirty minutes, yet people describe those minutes as among the most vivid experiences of their lives. It is also, remarkably, a molecule the human body appears to make in trace amounts, and one that occurs across an enormous range of plants. Our forthcoming book gives DMT the same whole-system treatment we gave the mushroom: the chemistry, the brain, the tradition, and the open edges.
What the Book Will Cover
Four ways into one molecule
The chemistry
A simple tryptamine built from tryptophan, why it's inactive by mouth alone, and how the ayahuasca brew changes that.
The brain
An agonist at the 5-HT2A serotonin receptor, the same doorway shared by psilocybin and LSD though a more weakly binding one than LSD, with other targets such as the sigma-1 receptor, and what "breakthrough" states reveal about perception.
The tradition
From Amazonian snuffs to the visionary lineage, and the enduring puzzle of a psychedelic the body itself seems to produce.
The clinic
Intravenous DMT in early trials in people with depression, and what a very short-acting experience means for research. These results come from people with a diagnosis and do not describe healthy adults.
The science in brief
DMT works, like most of the family, primarily through the brain's 5-HT2A serotonin receptor. Taken by mouth on its own it does almost nothing: the enzyme monoamine oxidase in the gut breaks it down before it can act. That single pharmacological fact is the hinge of the whole story: the Amazonian ayahuasca brew pairs DMT with a plant whose compounds block that enzyme.
Its clinical chapter is just opening. An intravenous DMT candidate was tested in an early-phase trial in people with depression, a clinical population, and the page describes the result as small and early. We hold the result and the uncertainty together.
Reliability: the receptor pharmacology is well established (strong). The clinical evidence is early-stage and preliminary. It comes from people with a diagnosis and does not describe healthy adults. Full sources will accompany the finished book.